Literature DB >> 25973032

Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model.

Xing Wang1, Juan Zhang2, Liang Zhou3, Peng Lu1, Zhi-Gang Zheng1, Wei Sun1, Jian-Lin Wang1, Xi-Sheng Yang1, Xiao-Lei Li1, Ning Xia1, Ning Zhang1, Ke-Feng Dou1.   

Abstract

MicroRNAs (miRNAs) are associated with human carcinogenesis and tumor development. Moreover, serum miRNAs can reflect the level of tissue miRNAs and be potential tumor markers. Serum microRNA-21 (miR-21) is overexpressed in many human cancers including hepatocellular carcinoma (HCC). However, how serum miR-21 changes during the HCC formation and whether miR-21 plays a regulatory role in this whole process are unknown. The current study evaluated the prognostic and diagnostic potential of serum miR-21 in HCC patients. Next, we established a HCC rat model and collected the blood and liver tissues at regular time points. AFP from the serum, RNA from the serum and liver tissues were collected and quantified separately. The results revealed that tissue and serum miR-21 was upregulated significantly in the groups of cirrhosis, early and advanced HCC compared with normal and fibrosis groups. The AFP levels were increased in early and advanced HCC compared with other groups. Then, the changes of miR-21 downstream proteins (i.e., programmed cell death 4 [PDCD4] and phosphatase and tensin homolog [PTEN]) in the liver tissues were measured. PDCD4 and PTEN expression was decreased gradually after tumor induction and negatively correlated with miR-21 expression. All these results suggested that serum miR-21 was associated with the prognosis of HCC; the changes in serum miR-21 were earlier and more accurately reflected the pathogenesis of HCC than AFP; therefore, it could be used as an early diagnostic marker for HCC. Our in vivo experiments further confirmed that miR-21 plays an important role in promoting the occurrence and development of HCC by regulating PDCD4 and PTEN.

Entities:  

Keywords:  Hepatocellular carcinoma; biomarker; diagnosis and prognosis; microRNA; microRNA-21; serum

Mesh:

Substances:

Year:  2015        PMID: 25973032      PMCID: PMC4396214     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  47 in total

Review 1.  The functions of animal microRNAs.

Authors:  Victor Ambros
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 2.  Mouse models of hepatocellular carcinoma.

Authors:  Nelson Fausto; Jean S Campbell
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 3.  How microRNAs control cell division, differentiation and death.

Authors:  Eric A Miska
Journal:  Curr Opin Genet Dev       Date:  2005-10       Impact factor: 5.578

4.  MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma.

Authors:  Changzheng Liu; Jia Yu; Shuangni Yu; Robert M Lavker; Lei Cai; Wei Liu; Kegong Yang; Xiaodong He; Songsen Chen
Journal:  J Hepatol       Date:  2010-04-04       Impact factor: 25.083

5.  Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression.

Authors:  Xing-xiang Pu; Guo-liang Huang; Hong-qiang Guo; Cheng-cheng Guo; Haoran Li; Shen Ye; Suxia Ling; Li Jiang; Ying Tian; Tong-yu Lin
Journal:  J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 4.029

6.  Circulating microRNAs in plasma of patients with gastric cancers.

Authors:  M Tsujiura; D Ichikawa; S Komatsu; A Shiozaki; H Takeshita; T Kosuga; H Konishi; R Morimura; K Deguchi; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

8.  Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype.

Authors:  Erin Connolly; Margherita Melegari; Pablo Landgraf; Tatyana Tchaikovskaya; Bud C Tennant; Betty L Slagle; Leslie E Rogler; Mihaela Zavolan; Thomas Tuschl; Charles E Rogler
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

9.  Lymphotoxins: new targets for hepatocellular carcinoma.

Authors:  Augusto Villanueva; Radoslav Savic; Josep M Llovet
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

10.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients.

Authors:  D M Barnes; W H Harris; P Smith; R R Millis; R D Rubens
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

View more
  14 in total

1.  MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.

Authors:  Kejia Wang; Qing Liang; Li Wei; Wei Zhang; Ping Zhu
Journal:  Tumour Biol       Date:  2015-10-16

2.  Emerging role of microRNA-21 in cancer.

Authors:  Yin-Hsun Feng; Chao-Jung Tsao
Journal:  Biomed Rep       Date:  2016-08-26

Review 3.  Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.

Authors:  Sijia Shen; Yuxin Lin; Xuye Yuan; Li Shen; Jiajia Chen; Luonan Chen; Lei Qin; Bairong Shen
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

4.  Prognostic value of microRNAs in hepatocellular carcinoma: a meta-analysis.

Authors:  Yue Zhang; Chao Wei; Cong-Cong Guo; Rong-Xiu Bi; Jin Xie; Dong-Hui Guan; Chuan-Hua Yang; Yue-Hua Jiang
Journal:  Oncotarget       Date:  2017-09-14

5.  Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis.

Authors:  Xin Guo; Xiaohui Lv; Xing Lv; Yueyun Ma; Lin Chen; Yong Chen
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  MicroRNA-Mediated Regulation of HMGB1 in Human Hepatocellular Carcinoma.

Authors:  Jianing Yan; Shibo Ying; Xiujun Cai
Journal:  Biomed Res Int       Date:  2018-01-31       Impact factor: 3.411

7.  Prognostic and diagnostic potential of miR-146a in oesophageal squamous cell carcinoma.

Authors:  Cong Wang; Shanghui Guan; Fang Liu; Xuan Chen; Lihui Han; Ding Wang; Effat Un Nesa; Xintong Wang; Cihang Bao; Nana Wang; Yufeng Cheng
Journal:  Br J Cancer       Date:  2016-01-21       Impact factor: 7.640

8.  Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.

Authors:  Soon Sun Kim; Hyo Jung Cho; Ji Sun Nam; Hyun Ji Kim; Dae Ryong Kang; Je Hwan Won; Jinoo Kim; Jai Keun Kim; Jei Hee Lee; Bo Hyun Kim; Mi Young Lee; Sung Won Cho; Jae Youn Cheong
Journal:  J Korean Med Sci       Date:  2018-01-01       Impact factor: 2.153

Review 9.  Role of Exosomal MicroRNAs and myomiRs in the Development of Cancer Cachexia-Associated Muscle Wasting.

Authors:  Rodolfo Marinho; Paulo S M Alcântara; José P Ottoch; Marilia Seelaender
Journal:  Front Nutr       Date:  2018-01-09

Review 10.  Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.

Authors:  Wataru Okajima; Shuhei Komatsu; Daisuke Ichikawa; Mahito Miyamae; Takuma Ohashi; Taisuke Imamura; Jun Kiuchi; Keiji Nishibeppu; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2017-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.